A Azzariti
Overview
Explore the profile of A Azzariti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Porcelli L, Stolfa D, Stefanachi A, Di Fonte R, Garofoli M, Iacobazzi R, et al.
Cancer Lett
. 2018 Dec;
445:1-10.
PMID: 30583077
We previously demonstrated that some N-biphenylanilides caused cell-cycle arrest at G2/M transition in breast cancer cells. Among them we choose three derivatives, namely PTA34, PTA73 and RS35 for experimentation in...
2.
Guida S, Bartolomeo N, Zanna P, Grieco C, Maida I, De Summa S, et al.
Arch Dermatol Res
. 2015 Mar;
307(6):495-503.
PMID: 25736238
Environmental and genetic risk factors are involved in the development of melanoma. The role of the melanocortin 1 receptor (MC1R) gene has been investigated and differences according to geographic areas...
3.
Bobba A, Amadoro G, Azzariti A, Pizzuto R, Atlante A
Biochim Biophys Acta
. 2014 Apr;
1837(8):1338-49.
PMID: 24709060
Apoptosis in neuronal tissue is an efficient mechanism which contributes to both normal cell development and pathological cell death. The present study explores the effects of extracellular ADP on low...
4.
Quatrale A, Porcelli L, Gnoni A, Numico G, Paradiso A, Azzariti A
Curr Med Chem
. 2013 Sep;
21(8):1039-49.
PMID: 23992324
Antivascular approaches aim to cause rapid and catastrophic shutdown in the vascular function of the tumour, leading to extensive tumour cell death. Tumour vascular disrupting agents (VDAs) are a new...
5.
Porcelli L, Quatrale A, Mantuano P, Silvestris N, Rolland J, Biancolillo L, et al.
Curr Pharm Des
. 2012 Sep;
19(5):918-26.
PMID: 22973960
Single-agent therapy with molecularly targeted agents has shown limited success in tumor growth control, mainly because escape or resistance mechanisms are activated once a signalling molecule is inhibited. Rational combinations...
6.
Porcelli L, Quatrale A, Mantuano P, Silvestris N, Brunetti A, Calvert H, et al.
Curr Med Chem
. 2012 Jul;
19(23):3858-73.
PMID: 22788762
A large body of evidence point out that the onset of synthetic lethality may provide a useful tool for amplifying the efficacy of drugs in anticancer regimens, to uncover interdependence...
7.
Porcelli L, Gilardi F, Laghezza A, Piemontese L, Mitro N, Azzariti A, et al.
J Med Chem
. 2011 Nov;
55(1):37-54.
PMID: 22081932
A series of ureidofibrate-like derivatives was prepared and assayed for their PPAR functional activity. A calorimetric approach was used to characterize PPARγ-ligand interactions, and docking experiments and X-ray studies were...
8.
Azzariti A, Bocci G, Porcelli L, Fioravanti A, Sini P, Simone G, et al.
Br J Cancer
. 2011 Feb;
104(5):769-80.
PMID: 21304529
Background: AZD1152, the prodrug for AZD1152-hydroxyquinazoline pyrazol anilide (HQPA), is a selective inhibitor of Aurora B kinase activity. Preclinical evaluation of AZD1152 has been reported in several human cancer models....
9.
Calvert H, Azzariti A
Ann Oncol
. 2011 Feb;
22 Suppl 1:i53-9.
PMID: 21285153
A number of inhibitors of DNA repair have been evaluated or are undergoing development as potential cancer treatments. Inhibitors of poly(ADP-ribose) polymerase (PARP) are of particular interest in treating hereditary...
10.
Silvestris N, Maiello E, De Vita F, Cinieri S, Santini D, Russo A, et al.
Cancer Treat Rev
. 2010 Dec;
36 Suppl 3:S46-55.
PMID: 21129610
Capecitabine is an orally administered fluoropyrimidine carbamate which has been developed as a prodrug of 5-FU with the goal to improve its tolerability and intratumoral drug concentration. The review aims...